...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
【24h】

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

机译：用贝伐单抗治疗的癌症患者不良心血管事件相关的因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. Methods and Results: We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose ( p 0.05), concomitant hypertension ( p = 0.005), diabetes ( p = 0.04), atrial fibrillation ( p = 0.03), and lack of use of statin therapy ( p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.
机译：背景：Bevacizumab，常用于治疗各种癌症的血管内皮生长因子（VEGF）单克隆抗体通常与不良心血管作用如高血压，心脏和脑缺血，血栓形成和出血事件有关。尚未集中研究与贝伐单抗的不良心血管作用增加相关的因素。在这项研究中，我们确定了由于接受癌症治疗的患者的心血管并发症，确定了与医院入学相关的因素。方法和结果：我们回顾性地收集了在2016年1月1日至2017年1月1日至2017年12月31日在猎人新英格兰当地卫生区治疗的所有患者的数据。患者的特征及其病史是从医院电子病历中获得的。结果数据来自机构心脏和中风结果单位数据库。总共N = 230名（平均年龄65，雄性N = 124（53.9％））在研究期间用Bevacizumab治疗。 n = 28名患者入院，为医院接受过大型心血管相关的事件。较高的总处理剂量（P <0.05），伴随高血压（P = 0.005），糖尿病（P = 0.04），心房颤动（P = 0.03），缺乏使用他汀类药物治疗（P = 0.03）是医院的关键贡献者入学。结论：我们的研究结果强调了伴随基线心血管疾病/危险因素的患者的事实是与Bevacizumab治疗有关的心血管住院风险的增加。仔细的基线心血管评估可能是最小化心血管并发症的重要步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号